Details of issuance or disposal
Acquisition and cancellation of Series 3 through Series 5 stock acquisition rights issued through a third-party allotment, with provisions for adjustment of the exercise price
Total potential shares subject to acquisition: 2,762,000 shares (Series 3: 362,000 shares; Series 4: 1,200,000 shares; Series 5: 1,200,000 shares)
Amount planned to be raised through these stock acquisition rights: ¥2,025,420,000; amount already raised: ¥399,726,000; amount not to be raised as a result of the acquisition and cancellation: ¥1,625,694,000
| Item | Details |
|---|---|
| Type of issuance or disposal | Acquisition and cancellation of Series 3 through Series 5 stock acquisition rights issued through a third-party allotment, with provisions for adjustment of the exercise price |
| Number of shares to be issued or disposed of | Total potential shares subject to acquisition: 2,762,000 shares (Series 3: 362,000 shares; Series 4: 1,200,000 shares; Series 5: 1,200,000 shares) |
| Amount of funds to be raised | Amount planned to be raised through these stock acquisition rights: ¥2,025,420,000; amount already raised: ¥399,726,000; amount not to be raised as a result of the acquisition and cancellation: ¥1,625,694,000 |
| Specific use of funds | Details Product procurement costs / Amount ¥399 million / Scheduled timing of expenditures January 2026 to June 2026 |
| Intended allottee | EVO FUND |
| Exercise price | The stock acquisition rights have an exercise price adjustment clause; the initial exercise price and adjustment floor are Not disclosed |
| Number of Stock Acquisition Rights | Total subject to acquisition: 27,620 rights; remaining after cancellation: 0 rights (Series 3: 3,620 rights; Series 4: 12,000 rights; Series 5: 12,000 rights) |
| Reason for acquisition without consideration | The Company will acquire all of these stock acquisition rights remaining on the acquisition date, pursuant to Article 14, Paragraph (1) of the issuance terms for each right. |
| Most recent equity financing | Timing 29 December 2025 / Type Third-party allotment of Series 3 through Series 5 stock acquisition rights with provisions for adjustment of the exercise price / Amount Planned proceeds: ¥2,025,420,000 |
| Impact on Business Performance | The impact of this matter on consolidated results for the fiscal year ending August 2027 is immaterial |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Sovereign GaiXer business has moved from a product development-focused phase to a phase focused on strengthening its sales structure and expanding its customer base. The Company therefore revised its policy to invest incrementally while monitoring order progress and the profitability of individual projects. It also cited the reduced capital efficiency of raising funds in advance when the timing of specific expenditures has not been determined, the possibility that the adjustment provisions for the exercise price could result in fundraising that does not match the amount or timing required, and the impact of dilution on existing shareholders.